2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 220-222
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transfusion, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Biological Processes, Pathogenesis, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, VWD, Genetic Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Young Adult
PAPER

878 Updated results from part 1 of the ReInspire study evaluating zovegalisib, a mutant-selective PI3Kα inhibitor, in adults and adolescents with PIK3CA-driven vascular malformations

Bryan Sisk, MD, Ionela Iacobas2, Shelley Crary, MD, MS3, Joyce Teng4, Eulalia Baselga5, Ahmad Al-Huniti, MD6, Alexandra Borst7, Adrienne Hammill, MD PhD8, Alessandro Mussa9, Satyamaanasa Polubothu10, Emmanuel Seront11, Beth Apsel Winger, MD, PhD12, Vivian Y Chang, MD, MS13, Beth Drolet14, Michael H White, MD, MSc15, Andrea Diociaiuti16, Manuel Gomez Tellado17, Melanie Jackson18, Michael Kelly19, Camille Skaer20, Paloma Triana21, Martin A. Robledo22, Xuemin Gu23, Caitlin Patriquin24, Sonia Singh25, Brenton G. Mar26, Juan Carlos Lopez-Gutierrez27
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Baylor College Of Medicine / Texas Children's Hospital, Houston, Texas, United States
3 Arkansas Hospital/ University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4 Stanford University, Palo Alto, California, United States
5 Hospital Sant Joan de Deu, Madrid, Spain
6 The Mayo Clinic, Rochester, Minnesota, United States
7 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
8 Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
9 A.O.U. Città della Salute e della Scienza di Torino (University of Torino), Torino, Italy
10 Great Ormond Street Hospital Foundation Trust, London, United Kingdom
11 UC Louvain, Louvain-la-Neuve, Belgium
12 UCSF Birthmarks and Vascular Center, San Francisco, California, United States
13 University of California, Los Angeles Health, Los Angeles, California, United States
14 University of Wisconsin, Madison, Wisconsin, United States
15 Emory School of Medicine, Aflac Cancer & Blood Disorders Center, Atlanta, Georgia, United States
16 Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy
17 Hospital Universitario de A Coruna, A Coruna, Spain
18 Children's Health Queensland Hospital and Health Service, South Brisbane, Australia
19 The Cleveland Clinic, Cleveland, Ohio, United States
20 Washington University School of Medicine, St. Louis, Missouri, United States
21 Hospital Universitario La Paz, Madrid, Spain
22 Relay Therapeutics, Cambridge, Massachusetts, United States
23 Relay Therapeutics, Cambridge, Massachusetts, United States
24 Relay Therapeutics, Cambridge, Massachusetts, United States
25 Relay Therapeutics, Cambridge, Massachusetts, United States
26 Relay Therapeutics, Cambridge, Massachusetts, United States
27 Hospital Universitario La Paz, Madrid, Spain

Purpose: Somatic mosaic mutations in PIK3CA during embryogenesis drive the development of vascular malformations including lymphatic malformations (LMs), PIK3CA-related overgrowth spectrum (PROS), and venous malformations (VMs). These highly symptomatic lesions cause lifelong morbidity, including severe pain, clotting, bleeding, mobility impairment, and developmental delay, and can lead to life-threatening complications such as airway compromise, pulmonary embolism and effusions, ascites, infections, and organ failure. Non-mutant selective PI3Kα pathway inhibitors, including alpelisib and sirolimus, inhibit the wildtype PI3Kα/mTOR pathway and lead to toxicities such as severe hyperglycemia, diarrhea, rash, stomatitis, infection, and growth delay, which potentially lead to discontinuation or use of subtherapeutic doses to avoid long term adverse events.

Zovegalisib is a novel, oral, mutant-selective PI3Kα inhibitor being studied in ReInspire (NCT06789913), a Phase 2 study for adult and pediatric participants with PIK3CA-driven vascular malformations.

Methods: The primary endpoints in the open-label dose-finding Part 1 are safety, tolerability, and recommended dose(s) selection. Group 1 participants (≥12 years) are randomized to zovegalisib 100, 300, or 400 mg BID. Additional efficacy endpoints include response (≥20% reduction in total lesion volume) on MRI by blinded independent central review and participant- and investigator-reported outcomes, including the Patient and Investigator Global Impression of Change (PGIC and IGIC), and well as the Investigators Assessment of Disease Related Signs and Symptoms (IADRSS).

Results: As of 15Apr26, 32 Group 1 participants (22 adult, 10 adolescents) with vascular malformations were randomized to receive zovegalisib, including 22 with PROS (predominantly KTS and CLOVES), 8 with LMs, and 2 with VMs. Median age was 24.5 years (range: 12-63); 26 (81%) had confirmed PIK3CA mutation, 10 (31%) with kinase-domain mutations; and 23 (72%) had prior systemic therapy with alpelisib and/or sirolimus. Of these 32 participants, 28 (87.5%) experienced at least one treatment-related AE (TRAE). Common TRAEs included headache, fatigue, nausea, diarrhea, hyperglycemia, and decreased appetite, which were generally low-grade, reversible, and dose dependent. Five grade ≥3 TRAEs occurred in 4 participants (12.5%) and were limited to the higher doses of 300 mg BID (n=2) and 400 mg BID (n=2). No grade ≥3 TRAEs were observed in the 100 mg BID cohort. All participants remained on treatment (range 2-40 weeks).

Of 20 participants with a post-baseline MRI, 12 (60%) achieved volumetric response (range -20.7% to -85% change), including 8 responders with prior alpelisib and/or sirolimus treatment. A dose response was observed with 6/6 (100%) responding at 300mg BID, all occurring at the first scan at 12 weeks, while 2/7 (29%) responded at 100mg BID.  Volumetric responses were observed regardless of diagnosis (PROS and LMs), PIK3CA mutation (kinase, helical and others) and prior therapy (alpelisib and sirolimus).   By week 12, overall symptom improvement was reported by 11/14 (79%) participants by PGIC and 17/19 (89%) investigators by IGIC.  The most frequently cited bothersome symptom was pain, which was improved in 15/21 (71%) at week 12.

Conclusion: Zovegalisib demonstrates encouraging safety and volumetric reduction in target lesions associated with notable clinical improvements in participants with PIK3CA-driven vascular malformations, including those with prior systemic treatment, consistent with zovegalisib’s mutant-selective activity.

Bryan Sisk, MD: VasqueBio - Consultancy (Includes expert testimony); Palvella Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); OnCusp Therapeutics - Consultancy (Includes expert testimony); OnKure Therapeutics - Consultancy (Includes expert testimony); Relay Therapeutics - Consultancy (Includes expert testimony); Gilead Sciences - Consultancy (Includes expert testimony); Palinos - Consultancy (Includes expert testimony); Kaken Pharmaceuticals - Consultancy (Includes expert testimony)